CLGN

CollPlant Biotechnologies Ltd Ordinary Shares

0.75

USD

CLGN Earnings Reports

Positive Surprise Ratio

CLGN beat 3 of 25 last estimates.

12%

Next Report

Today BMO

Date of Next Report

Mar 26, 2026

Estimate for Q4 25 (Revenue/ EPS)

$1.55M

-$0.19

Implied change from Q3 25 (Revenue/ EPS)

+1919.47%

-29.63%

Implied change from Q4 24 (Revenue/ EPS)

+848.16%

-44.12%

CollPlant Biotechnologies Ltd Ordinary Shares earnings per share and revenue

On Nov 26, 2025, CLGN reported earnings of -0.27 USD per share (EPS) for Q3 25, missing the estimate of 0.15 USD, resulting in a -270.78% surprise. Revenue reached 77.00 thousand, compared to an expected 4.94 million, with a -98.44% difference. The market reacted with a -0.45% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 1.55 million USD, implying an decrease of -29.63% EPS, and increase of 1919.47% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

BioCardia, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.17

Actual

-$0.06

Surprise

+65.40%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

FAQ

What were CollPlant Biotechnologies Ltd Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, CollPlant Biotechnologies Ltd Ordinary Shares reported EPS of -$0.27, missing estimates by -270.78%, and revenue of $77.00K, -98.44% below expectations.

How did the market react to CollPlant Biotechnologies Ltd Ordinary Shares's Q3 2025 earnings?

The stock price moved down -0.45%, changed from $2.24 before the earnings release to $2.23 the day after.

When is CollPlant Biotechnologies Ltd Ordinary Shares expected to report next?

The next earning report is scheduled for Mar 26, 2026.

What are the forecasts for CollPlant Biotechnologies Ltd Ordinary Shares's next earnings report?

Based on 4 analysts, CollPlant Biotechnologies Ltd Ordinary Shares is expected to report EPS of -$0.19 and revenue of $1.55M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.